Toksin Botulinum untuk Kasus Urogenital
DOI:
https://doi.org/10.55175/cdk.v48i3.55Kata Kunci:
Kasus urogenital, neurotoksin, toksin botulinumAbstrak
Toksin Botulinum merupakan neurotoksin yang diproduksi oleh bakteri Clostridium. Neurotoksin menempel pada terminal kolinergik perifer dan menghambat pelepasan asetilkolin, menyebabkan relaksasi otot. Efek ini bermanfaat untuk beberapa kasus uroginekologi, seperti overaktivitas detrusor, painful bladder syndrome, nyeri pelvis kronik, vaginismus, vulvodynia lokal, dan disfungi ereksi.
Botulinum toxin is a neurotoxin produced by Clostridium bacteria. Neurotoxins attach to the peripheral cholinergic terminal and inhibit acetylcholine release, causing musclerelaxation. This effect is used as a therapeutic option for some urogynaecological cases, such as detrusor overactivity, painful bladder syndrome, chronic pelvic pain, vaginismus, local vulvodynia, and erectile dysfunction.
Unduhan
Referensi
Ghanem H, Raheem AA, Rahman IFSA, Johnson M, Abdel-Raheem T. Botulinum neurotoxin and its potentioal role in the treatment of erectile dysfunction. Sex Med Rev. 2018;6:135-42.
Aoki KR. Pharmacology and immunology of botulinum toxin serotypes. J Neurol. 2001;248 (Suppl 1):3-10.
Moga MA, Dimienescu OG, Balan A, Scarneciu I, Barabas B, Ples L. Therapeutic approaches of botulinum toxin in gynecology. Toxins. 2018;10(4):169. doi:10.3390/ toxins10040169.
Davies JR, Liu SM, Acharya KR. Variations in the botulinum neurotoxin binding domain and the potential for novel therapeutics. Toxins. 2018;10(10):421. Doi:10.3390/toxins10100421.
Sinha D, Karri K, Arunkalaivanan AS. Application of botulinum toxin in urogynaecology. Eur J Obstet Gynecol Reprod Biol. 2007;133(1):4-11
Drake MJ. Overactive bladder. In: Wein AJ, Kavoussi L, Partin AW, Peters CA, editors. Campbell-Walsh Urology. 11th ed. Philadelphia: Elsevier; 2016 .p. 1796-805
Burkhard FC, Lucas M, Berghmans LC, Bosch JLHR, Cruz F, Lemack E, et al. EAU guidelines on urinary incontinence in adults. 2016. ISBN 978-90-79754-98-4
Gormley E, Lightner D, Burgio K, Chai T, Clemens J, Culkin D, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults. AUA/SUFU Guideline. J Urol. 2012;188(6):2455-63
Harper M, Popat RB, Dasgupta R, Fowler CJ, Dasgupta P. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003;92:325–6.
Radziszewski P, Borkowski A. Botulinum toxin type A intravesical injections for instable bladder overactivity. Eur Urol Suppl 2002;1(1):134 [Abstract 526].
Schmid DM, SauermannP, Werner M, Schuessler B, Blick N, Muentener M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177–85.
Lamarre NS, Bjorling DE. Treatment of painful bladder syndrome/interstitial cystitis with botulinum toxin A: why isn’t it effective in all patients? Transl Androl Urol. 2015;4(5):543-54
Stratton P, Khachikyan I, Sinaii N, Ortiz R, Shah J. Association of chronic pelvic pain and endometriosis with signs of sensitization and myofascial pain. Obstet Gynecol. 2015;125:719–28
Hoffman D. Central and peripheral pain generators in women with chronic pelvic pain: Patient centered assessment and treatment. Curr Rheumatol Rev.2015;11:146–66.
Stratton P, Berkley KJ. Chronic pelvic pain and endometriosis: Translational evidence of the relationship and implications. Hum Reprod Update. 2011;17:327–46.
Karp BI, Tandon H, Vigil D, Stratton P. Methodological approaches to botulinum toxin for treatment of chronic pelvic pain, vaginismus and vulvar pain disorders. Int Urogynecol J. 2019;30(7):1071-81 doi:10.007/s00192-018-3831-z
Bahat PY, Çetin BA, Turan G. Vaginismus treatment with libido increase and practice. Int. J. Reprod. Contracept. Obstet. Gynecol. 2017;6:3167–9.
Lamont JA. Vaginismus. Am J Obstet Gynecol. 1978;131:633–6
Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol. 2004;104:922–5.
Pacik PT, Geletta S. Vaginismus treatment: Clinical trials follow up 241 patients. Sex Med. 2017;5:114-23
Goldstein AT, Marinoff SC, Haefner HK. Vulvodynia: Strategies for treatment. Clin Obstet Gynecol. 2005;48:769–85.
Yoon H, Chung WS, Shim BS. Botulinum toxin A for management of vulvodynia. Internat J Impotence Res. 2007;19:84-7
Ghanem H, Raheem AH, Rahman IFSA, Johnson M, Abdel-Raheem T. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sex Med Rev. 2018; 6:135e142
Ghanem H, Soliman I, AbdulHamid M, Shamloul R. Can intracavernosal botulinum toxin injection salvage vascular erectile dysfunction patients not responding to oral and intracavernous therapy? A pilot study. J Sex Med 2016;13(Suppl 2):116
Ghanem H, Abd El Raheem A, Soliman I. Botox for erectile dysfunction [Internet]. 2017. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03102762.
De Young L, Campbell J, Radomski S, Alzubaidi R, Brock G. Intracavernosal injection of botulinum toxin to improve erectile function in older rats. J Sex Med 2017;14(Suppl 1):40-1
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2021 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
